Invesco’s Clovis Oncology, Inc. CLVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-49,947
Closed -$101K 4202
2022
Q1
$101K Buy
49,947
+704
+1% +$1.38K ﹤0.01% 3867
2021
Q4
$134K Sell
49,243
-1,572
-3% -$5.81K ﹤0.01% 3859
2021
Q3
$227K Buy
50,815
+10,743
+27% +$51.7K ﹤0.01% 3758
2021
Q2
$232K Buy
40,072
+19,254
+92% +$113K ﹤0.01% 3739
2021
Q1
$146K Buy
20,818
+4,114
+25% +$27.6K ﹤0.01% 3715
2020
Q4
$80K Buy
+16,704
New +$84.5K ﹤0.01% 3674
2020
Q1
Sell
-117,780
Closed -$1.23M 3758
2019
Q4
$1.23M Buy
117,780
+102,878
+690% +$748K ﹤0.01% 2892
2019
Q3
$59K Sell
14,902
-558
-4% -$4.51K ﹤0.01% 3645
2019
Q2
$230K Sell
15,460
-531
-3% -$9.59K ﹤0.01% 3583
2019
Q1
$397K Buy
+15,991
New +$401K ﹤0.01% 3393
2018
Q4
Sell
-326,122
Closed -$9.58M 3898
2018
Q3
$9.58M Sell
326,122
-16,979
-5% -$657K ﹤0.01% 1730
2018
Q2
$15.6M Sell
343,101
-3,985
-1% -$194K 0.01% 1386
2018
Q1
$18.3M Sell
347,086
-6,959
-2% -$406K 0.01% 1211
2017
Q4
$24.1M Sell
354,045
-126,537
-26% -$8.85M 0.01% 1115
2017
Q3
$39.6M Buy
480,582
+69,558
+17% +$5.51M 0.01% 878
2017
Q2
$38.5M Sell
411,024
-16,540
-4% -$1.01M 0.01% 897
2017
Q1
$27.2M Buy
427,564
+313,266
+274% +$19M 0.01% 1044
2016
Q4
$5.08M Buy
114,298
+103,193
+929% +$3.63M ﹤0.01% 1971
2016
Q3
$400K Buy
+11,105
New +$238K ﹤0.01% 3344
2016
Q1
Sell
-86,399
Closed -$3.02M 3785
2015
Q4
$3.02M Sell
86,399
-101,023
-54% -$6.52M ﹤0.01% 2263
2015
Q3
$17.2M Buy
187,422
+45,164
+32% +$3.91M 0.01% 1214
2015
Q2
$12.5M Buy
142,258
+35,538
+33% +$3.04M ﹤0.01% 1438
2015
Q1
$7.92M Sell
106,720
-61,911
-37% -$4.37M ﹤0.01% 1669
2014
Q4
$9.44M Buy
168,631
+15,878
+10% +$834K ﹤0.01% 1553
2014
Q3
$6.93M Buy
152,753
+9,964
+7% +$416K ﹤0.01% 1720
2014
Q2
$5.91M Sell
142,789
-13,971
-9% -$720K ﹤0.01% 1846
2014
Q1
$10.9M Buy
156,760
+115,430
+279% +$8.48M ﹤0.01% 1477
2013
Q4
$2.49M Buy
+41,330
New +$2.25M ﹤0.01% 2524
2013
Q3
Sell
-10,021
Closed -$671K 4353
2013
Q2
$671K Buy
+10,021
New +$451K ﹤0.01% 3130

Other funds holding CLVS